



Received: May 16, 2017
Revised: June 14, 2017
Accepted: July 11, 2017

Funding information: There was no funding source for this study.

Correspondence to:
Seung Eun Jung, M.D.
Department of Radiology,
Seoul St. Mary's Hospital,
College of Medicine,
The Catholic University of Korea,
222 Banpo-daero, Seocho-gu,
Seoul 06591, Korea.
Tel. +82-2-2258-1428
Fax. +82-2-599-6771
E-mail: sejung@catholic.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2017 Korean Society of Magnetic Resonance in Medicine (KSMRM)

Multiparametric MRI of Prostate Cancer after Biopsy: Little Impact of Hemorrhage on Tumor Staging

Moon Hyung Choi^{1,2}, Seung Eun Jung^{1,2}, Yong Hyun Park^{2,3}, Ji Youl Lee^{2,3}, Yeong-Jin Choi⁴

¹Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

²Catholic Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea

³Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁴Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Purpose: To evaluate differences in staging accuracy of prostate cancer according to the extent of hemorrhage on multiparametric MRI performed after biopsy.

Materials and Methods: We enrolled 71 consecutive patients with biopsy-proven prostate cancer. Patients underwent MRI followed by a prostatectomy at our institution in 2014. Two radiologists reviewed the MRI to determine the tumor stage. Correlation between biopsy-MRI interval and extent of hemorrhage was evaluated. Regression analyses were used to determine factors associated with accuracy of tumor staging.

Results: The mean interval between biopsy and MRI was 17.4 ± 10.2 days (range, 0–73 days). The interval between prostate biopsy and MRI and the extent of hemorrhage were not significantly correlated ($P = 0.880$). There was no significant difference in the accuracy rate of staging between the small and large hemorrhage groups.

Conclusion: Biopsy-induced hemorrhage in the prostate gland is not sufficiently absorbed over time. The extent of hemorrhage and the short interval between biopsy and MRI may not impair tumor detection or staging on multiparametric MRI.

Keywords: Prostatic neoplasms; Magnetic resonance imaging; Biopsy; Neoplasm staging; Hemorrhage

INTRODUCTION

Multiparametric MRI (mpMRI) has various roles in prostate cancer management including detection, staging, localization, and aggressive evaluation (1–9). Although many studies revealed the usefulness of mpMRI before transrectal ultrasound (TRUS)-guided biopsy (10–13), prostate MRI is still commonly performed after diagnosis of prostate cancer by TRUS-guided biopsy. As post-biopsy hemorrhage has been thought to decrease detection and staging accuracy of MRI in prostate cancer, prostate MRI is recommended to be performed more than eight weeks after the biopsy to provide time

for regression of the hemorrhage in the prostate gland (14–16).

According to recent guidelines, delaying MRI after biopsy for tumor detection may be unnecessary, although a delay of six weeks or longer should be considered for staging (17). However, mpMRI allows reasonable diagnostic accuracy, even after biopsy (18). The hemorrhage exclusion sign (HES) can be helpful to delineate prostate cancer in a hemorrhagic background (19). Moreover, as a biopsy cannot precisely predict the clinical significance of prostate cancer, delaying the MRI for six weeks can be problematic for some patients (20–22). If mpMRI can provide good accuracy for the staging of prostate cancer in post-biopsy patients, MRI does not have to be delayed after biopsy.

The purpose of this study was to evaluate differences in the staging accuracy of prostate cancer according to the extent of hemorrhage on mpMRI performed after biopsy.

MATERIALS AND METHODS

Subjects

This retrospective study was approved by the Institutional Review Board and the requirement for informed consent was waived. We identified 78 consecutive patients that were diagnosed with prostate cancer after 12-core TRUS-guided biopsy followed by prostate MRI and prostatectomy at our institution in 2014. We excluded seven patients that did not have prostatectomy specimen histologic maps. A total of 71 patients with a mean age of 66.6 (range, 49–78 years) were enrolled in this study. The mean interval between biopsy and MRI was 17.4 ± 10.2 days (range, 0–73 days). An interval between prostate biopsy and MRI greater than 21 days was considered a long interval.

MRI Technique

MRI was performed on 44 patients with 3-T (MAGNETOM Verio; Siemens Healthcare, Erlangen, Germany) system and 1.5-T MRI system (Achieva, Phillips, Best, The Netherlands) with a pelvic-phased array coil was used in the other 27 patients. In the absence of contraindications, 20 mg of scopolamine butylbromide (Buscopan; Boehringer Ingelheim, Ingelheim, Germany) was injected intramuscularly before MRI examination in order to reduce bowel movements.

The study protocol consisted of sagittal, coronal, and axial T2-weighted turbo spin echo (TSE) images (repetition time [TR] > 3200 ms, echo time [TE] 80–100 ms; echo train length, 14–18; matrix, 320×320 [3-T] or 210×210 [1.5-

T]; slice thickness, 3 mm; field of view [FOV], 160 mm; in-plane resolution 0.5×0.5 mm [3-T] or 0.8×0.8 mm; flip angle, 140° or 90°), axial T1-weighted TSE images (TR 400 ms, TE 10 ms; slice thickness, 3mm; matrix, 320×320 [3-T] or 210×210 [1.5-T]; FOV, 160 mm; in-plane resolution 0.5×0.5 mm [3-T] or 0.8×0.8 mm; flip angle, 150° or 90°), and axial diffusion-weighted images (DWI, b value 0, 50, 500, and 1000 [3-T] or 0, 500, and 1000 [1.5-T]; slice thickness, 3 mm; matrix, 100×100 [3-T] or 106×69 [1.5-T]; FOV, 210 mm [3-T] or 160 mm [1.5-T]; in-plane resolution, 2.1×2.1 mm [3-T] or 1.5×2.3 mm [1.5-T]). Apparent diffusion-coefficient (ADC) maps were generated from DWI with b values of 50 and 1000 sec/mm^2 in a 3-T MRI and 0 and 1000 sec/mm^2 in a 1.5-T MRI. The dynamic contrast-enhanced (DCE) images were acquired for more than 4 minutes with 0.1 mmol/kg gadobutol (Gadovist, Bayer Schering Pharma, Berlin, Germany) and temporal resolution was 5–7s. In-plane resolution was 0.9×1.2 mm in a 3-T MRI and 1.0×1.0 mm in a 1.5-T MRI. Subtraction DCE images were not used for image analysis.

Image Analysis

Two radiologists with 22 and 5 years of experience in prostate imaging reviewed all prostate MRIs in consensus using a picture archiving and communication system (Maroview version 5.4, INFINTT Healthcare, Seoul, Korea). The reviewers were aware that the patients had been diagnosed with prostate cancer by TRUS biopsy but were not aware of the Gleason score or the size and location of prostate cancer that was confirmed after prostatectomy.

Peripheral and transition zones were demarcated on T2-weighted images (T2-WI), although the transition zone was not evaluated to determine the extent of hemorrhage in this study due to intrinsic heterogeneous signal intensity. The prostate gland peripheral zone was divided into 12 regions on the MRI: right and left sides of lateral and medial regions at the apex, middle, and base of the prostate gland (Fig. 1). Hemorrhage in each region was assessed using axial T1-weighted images (T1-WI). Hemorrhage was considered to be present when high signal intensity occupied the region. Patients with hemorrhage in more than 6 regions were classified in the large hemorrhage group.

The radiologists evaluated the local stage of the prostate cancer after reviewing the T2-WI, DWI, and DCE images. A mass with marked hypointensity on an ADC map with homogeneous signal intensity (SI) lower than the normal peripheral zone on T2-WI and early enhancement on DCE was regarded as prostate cancer on MRI. It is important

for treatment plans to distinguish between non-organ-confined (pathologic stage $\geq T3$) cancer and organ-confined (pathologic stage $\leq T2$) cancer; therefore, we focused on increased sensitivity in order to diagnose non-organ-confined cancer. Non-organ-confined cancers include tumors with extracapsular extension (ECE), seminal vesicle invasion, and adjacent organ invasion. For tumor staging, we applied features indicating possibility of ECE suggested in Prostate Imaging - Reporting and Data System version 2 (PI-RADS v2). They included broad capsular contact (≥ 1 cm); capsular bulging; an irregular, spiculated, or angulated prostatic margin adjacent to the tumor; obliteration of the rectoprostatic angle; or thickening of the neurovascular bundle (17). When a tumor was not visible, we considered the tumor as organ-confined cancer. The HES suggested in a previous study was evaluated. The HES was defined as a well-defined area of a low-signal intensity nodule with surrounding high signal intensity on T1-WI (19).

MRI and Histology Correlation

Correlations between MRI findings and histologic results were assessed for each patient based on a histologic report and a histologic map where prostate cancers were marked. For local staging, accurate discrimination between organ-confined and non-organ-confined cancers on MRI was considered as correct. Images of tumors with incorrect MRI staging were reviewed with a histologic map to evaluate the causes of incorrect staging. Gleason score and tumor volume in each patient were collected from a histologic report.

Statistical Analysis

The Spearman correlation coefficient (r) was used to investigate the correlation between the number of hemorrhaged areas among 12 regions of the peripheral

zone and the TRUS biopsy and MRI interval.

Differences in the frequency of correct staging of prostate cancers according to the extent of hemorrhage, interval between biopsy and MRI, magnetic field strength of MRI unit, T stage, HES, tumor volume, and Gleason score were assessed using Fisher's exact test. Univariate and multivariate logistic regression analyses were performed to determine factors that were associated with tumor staging. Variables with P value less than 0.25 in the univariate analysis were included in the multivariate regression analysis. Statistical analysis was performed with SPSS 24.0 (IBM Corporation, Armonk, NY, USA). A P value less than 0.05 was considered statistically significant.

RESULTS

Patient and Tumor Characteristics

Local stages of prostate cancers were T2a ($n = 6$), T2b ($n = 5$), T2c ($n = 33$), T3a ($n = 13$), T3b ($n = 11$) and T4 ($n = 2$) in 71 patients. Gleason scores of prostatectomy specimens were 6 (3 + 3, $n = 6$), 7 (3 + 4, $n = 28$), 7 (4 + 3, $n = 23$), and more than 8 ($n = 14$). There were 10 prostate cancers primarily located in the transition zone and only one of them showed ECE while 9 prostate cancers were organ-confined: T2a ($n = 2$), T2b ($n = 2$) and T2c ($n = 5$). There were 15 tumors less than 0.5 mL in volume.

Image Analysis

For all patients, the median number of hemorrhaged areas was eight (range 0-12), and there was no biopsy-related hemorrhage in three patients. Large and small amounts of hemorrhaging were divided into groups that consisted of 49 and 22 patients, respectively. There was no statistically significant correlation between the interval between




Fig. 1. Schematic illustration of MRI shows 6 areas to evaluate hemorrhage in the right peripheral zone of the prostate.




Fig. 2. Extent of hemorrhage and time interval between biopsy and MRI. No statistically significant correlation was identified for time interval between transrectal ultrasound-guided biopsy and MRI ($r = -0.018$, $P = 0.880$).

prostate biopsy and MRI and the number of hemorrhaged areas ($r = -0.018$, $P = 0.880$) (Fig. 2).

Preoperative MRI staging was accurate in 61 of 71 patients (85.9%). There was no visible prostate cancer in 16 patients (22.5%). Invisible cancers were confirmed as organ-confined cancers after prostatectomy and they had variable Gleason scores: 6 (3 + 3, $n = 3$), 7 (3 + 4, $n = 8$), 7 (4 + 3, $n = 3$), and more than 8 ($n = 2$). However, there was no invisible cancer in inaccurately staged cancers. Based on all of the tested factors including the extent of hemorrhage, interval between biopsy and MRI, and HES, there was no significant difference in staging accuracy. Since there was no factor with P value less than 0.25 identified with the univariate analysis, multivariate analysis was not performed (Table 1). Accurate staging was documented in 23 of the 26 non-organ-confined cancers (sensitivity 88.5% and specificity 84.4%). Prostate cancer with accurate preoperative staging on MRI was displayed in Figure 3. Seven T2 cancers were over-staged as T3 cancers on MRI, and three T3 cancers were under-staged as T2 cancers on MRI. Of the seven over-staged cases, hemorrhage was considered as prostate cancer in one patient, and six patients had prostate cancer with broad contact up to the prostate capsule. Among the three under-staged cases, readers could not detect focal invasion in the seminal vesicle in two patients and could not detect extracapsular extension due to tumor located at the apex in

one patient. The patient with large amount of hemorrhage in the prostate gland is shown in Figure 4.

DISCUSSION

In this study, the extent of hemorrhage in the prostate gland was not correlated with the interval between prostate biopsy and MRI, which is in agreement with the results of a previous study (18). There was no significant difference in the accuracy rate of tumor staging between the large and the small hemorrhage groups and there was no factor that was associated with tumor staging accuracy.

Accuracy of MRI staging was not associated with any factors in this study. Hemorrhaging was considered as a prostate cancer lesion in only one patient, contrary to a previous study that showed there was a tendency to overestimate tumor presence and ECE on MRI that was performed less than 21 days after biopsy (14). MRI in a previous study consisted only of T1-WI and T2-WI, and the authors did not discriminate between hemorrhage and tumor; therefore, it is possible hemorrhage could have been mistaken as a tumor. In contrast, we were able to differentiate between hemorrhage and tumors and accurately determine tumor staging with mpMRI consisting of T2-WI, T1-WI, DWI, and DCE (18).

When conducting image analysis in the prostate gland with background hemorrhage, HES might be useful to detect prostate cancer (19). However, there were many invisible tumors in this study and some of them had high Gleason scores. Large amount of hemorrhage, small size of the prostate cancer, and low Gleason score can be reasons for invisibility. Nevertheless, all invisible tumors were organ-confined. Furthermore, staging accuracy was not statistically different between HES-negative and HES-positive patients. Since tumor staging is solely determined from the relationship between the tumor and the prostate capsule, HES seems to be useless to determine tumor staging and all inaccurately staged tumors were visible. So, invisibility might not impair staging accuracy.

Six organ-confined-cancers ($\leq T2$) had broad contact to the capsule and were over-staged as T3 cancers on preoperative MRI. We considered the tumor's broad capsular contact ≥ 1 cm as an ECE finding in this study. However, a previous study showed that 2 cm of tumor contact length was the best threshold to predict ECE (23). Over-staging for tumor with broad capsular contact may be caused by a 1 cm cut-off in our study. Broad capsular contact ≥ 1 cm

is described in PI-RADS v2 but > 1.5 cm was used in PI-RADS v1 (24), so the cut-off is still controversial. On the other hand, focal invasion into the seminal vesicle and the location of the tumor were the causes of inaccurate staging in under-staged cancers of our study. Microscopic invasion of the adjacent organ could not be accurately detected on MRI.

MRI may be utilized for prostate cancer detection any time after biopsy; however, a delay of more than 6-8 weeks post-biopsy has been recommended for prostate cancer staging (14, 16, 17). The necessity of this long interval is based on the belief that hemorrhage resolves 6-8 weeks after biopsy. However, in this study the extent of hemorrhage in the prostate gland was not correlated with the interval between prostate biopsy and MRI, and several

studies have also shown that absorption of hemorrhage was insufficient even after 6 weeks (18, 25, 26). A long interval between biopsy and MRI does not seem to guarantee hemorrhage absorption in the prostate gland. Moreover, large amount of hemorrhage did not significantly impact tumor staging.

There were a few limitations in this study. First, because of the retrospective study design, we were not able to control the interval between biopsy and MRI. The median interval was 17 days in this study, relatively shorter than recommended (17). The insufficient hemorrhage regression in the prostate gland could be attributable to the relatively short interval between biopsy and MRI. However, there was no correlation between amount of hemorrhage and delay time to MRI in our study and we wanted to evaluate


Table 1. Relationships between Clinical Factors and Tumor Staging

	Staging		P value ^a	Univariate regression	
	Correct (n = 61)	Incorrect (n = 10)		Odds ratio ^b	P value
Hemorrhage			1.000	1.056 (0.246, 4.532)	0.942
Small	19	3			
Large	42	7			
Interval:					
biopsy ~ MRI			0.261	2.238 (0.553, 9.066)	0.259
≤ 21 days	47	6			
> 21 days	14	4			
MRI			1.000	1.067 (0.429, 2.653)	0.890
3T	23	4			
1.5T	38	6			
T stage			0.736	0.708 (0.166, 3.013)	0.640
≤ T2	38	7			
≥ T3	23	3			
HES			0.738	1.346 (0.353, 5.138)	0.664
-	35	5			
+	26	5			
Tumor volume			0.106	-	0.998
< 0.5 mL	15	0			
≥ 0.5 mL	46	10			
Gleason score			0.585	-	0.998
≤ 6	6	0			
≥ 7	55	10			


HES = hemorrhage exclusion sign; MRI = magnetic resonance imaging

^aResults of the Fisher's exact test.


^bData in parentheses are 95% confidence intervals.




a



b



c




d




e


Fig. 3. A prostate cancer with accurate preoperative stage in a 58-year-old man. There is a small conspicuous lesion (arrow) with T2-low signal intensity (SI) (a) and T1-low SI surrounding T1-high SI (b) in the right peripheral zone. The corresponding area (arrows) shows high SI on diffusion-weighted image (c) and low apparent diffusion-coefficient value (d). MRI was performed nine days after transrectal ultrasound-guided biopsy, and there was a large amount of hemorrhage in the prostate gland (10 of 12 areas). The tumor was classified as an organ-confined cancer (dashed circle) on MRI and no extracapsular extension was confirmed after prostatectomy (e).




a




b



c



d



e

Fig. 4. Large amount of hemorrhage (arrows) in the prostate gland of a 64-year-old man. There are ill-defined T2-low signal intensity (SI) (a) and T1-high SI areas (b) in both peripheral zones. The corresponding area shows heterogeneous SI on diffusion-weighted image (c); apparent diffusion-coefficient value was not decreased (d). MRI was performed 18 days after transrectal ultrasound-guided biopsy, and there was a large amount of hemorrhage in the prostate gland (all 12 areas of the prostate gland). After prostatectomy, there was no tumor in either peripheral zone at this section (e).

the impact of hemorrhage on tumor staging. Future study with repeated MRI at each time point after biopsy will solve the problem. Second, two radiologists reviewed MRI in consensus rather than independently. There was a large difference in the two radiologists' experience, and since we were not sure about reaching proper inter-observer agreement in image analysis of the prostate with large amounts of hemorrhage, we interpreted MRI in consensus. Third, we did not use PI-RADS v2 for image analysis. As PI-RADS v2 categorization is decided without considering T1 signal intensity, many hemorrhagic areas may be rated as PI-RADS 4 or 5 in spite of their T1 high-SI. Therefore, we concluded that PI-RADS v2 was not meaningful in this study.

In conclusion, biopsy-induced hemorrhage in the prostate gland is not absorbed sufficiently over time. The extent of hemorrhage and the short interval between biopsy and MRI may not impair tumor detection or staging on multiparametric MRI.

Acknowledgments

This work was supported by the abdominal MRI study group of the Korean Society of Magnetic Resonance in Medicine (KSMRM).

REFERENCES

1. Bittencourt LK, de Hollanda ES, de Oliveira RV. Multiparametric MR imaging for detection and locoregional staging of prostate cancer. *Top Magn Reson Imaging* 2016;25:109-117
2. Chamie K, Sonn GA, Finley DS, et al. The role of magnetic resonance imaging in delineating clinically significant prostate cancer. *Urology* 2014;83:369-375
3. Delongchamps NB, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. *BJU Int* 2011;107:1411-1418
4. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. *Eur Urol* 2011;59:477-494
5. Hoeks CM, Barentsz JO, Hambroek T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. *Radiology* 2011;261:46-66
6. Turkbey B, Brown AM, Sankineni S, Wood BJ, Pinto PA, Choyke PL. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. *CA Cancer J Clin* 2016;66:326-336
7. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. *Radiology* 2010;255:89-99
8. Ueno Y, Tamada T, Bist V, et al. Multiparametric magnetic resonance imaging: Current role in prostate cancer management. *Int J Urol* 2016;23:550-557
9. Kim TH, Jeong JY, Lee SW, et al. Diffusion-weighted magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance. *Eur Radiol* 2015;25:1786-1792
10. Abd-Alazeez M, Ahmed HU, Arya M, et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer? *Urol Oncol* 2014;32:45 e17-22
11. Fütterer JJ, Briganti A, De Visschere P, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. *Eur Urol* 2015;68:1045-1053
12. Park BK, Park JW, Park SY, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. *AJR Am J Roentgenol* 2011;197:W876-881
13. Porpiglia F, Manfredi M, Mele F, et al. Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy-naive patients with suspected prostate cancer. *Eur Urol* 2017;72:282-288
14. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. *Radiology* 1995;195:385-390
15. Qayyum A, Coakley FV, Lu Y, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. *AJR Am J Roentgenol* 2004;183:1079-1083
16. Ko YH, Song PH, Moon KH, Jung HC, Cheon J, Sung DJ. The optimal timing of post-prostate biopsy magnetic resonance imaging to guide nerve-sparing surgery. *Asian J Androl* 2014;16:280-284
17. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. *Eur Urol* 2016;69:16-40
18. Tamada T, Sone T, Jo Y, et al. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. *Radiology* 2008;248:531-539
19. Barrett T, Vargas HA, Akin O, Goldman DA, Hricak H. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. *Radiology*

- 2012;263:751-757
20. Iremashvili V, Pelaez L, Jorda M, et al. Prostate sampling by 12-core biopsy: comparison of the biopsy results with tumor location in prostatectomy specimens. *Urology* 2012;79:37-42
21. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. *J Urol* 2001;166:104-109; discussion 109-110
22. Kim JW, Park HK, Kim HG, et al. Discordance between location of positive cores in biopsy and location of positive surgical margin following radical prostatectomy. *Korean J Urol* 2015;56:710-716
23. Baco E, Rud E, Vlatkovic L, et al. Predictive value of magnetic resonance imaging determined tumor contact length for extracapsular extension of prostate cancer. *J Urol* 2015;193:466-472
24. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. *Eur Radiol* 2012;22:746-757
25. Ikonen S, Kivisaari L, Vehmas T, et al. Optimal timing of post-biopsy MR imaging of the prostate. *Acta Radiol* 2001;42:70-73
26. Sharif-Afshar AR, Feng T, Koopman S, et al. Impact of post prostate biopsy hemorrhage on multiparametric magnetic resonance imaging. *Can J Urol* 2015;22:7698-7702